Targeting Metastatic Melanoma
- 18 February 2012
- journal article
- review article
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 63 (1) , 171-183
Abstract
Metastatic melanoma has historically been one of the most treatment-refractory types of cancer. Recent headway has been made in understanding the genetic underpinnings of this cancer. A subset of oncogenic events is amenable to targeting with drug therapy. BRAF-targeted therapies represent the first major breakthrough in systemic therapy for melanoma leveraging the new genetic knowledge. Ongoing translational research seeks to identify the most scientifically rational combination treatment strategies to build on single-agent targeted therapy.Keywords
This publication has 49 references indexed in Scilit:
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3KCancer Cell, 2010
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivationNature, 2010
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationNature, 2010
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaNature, 2010
- IRF4 Variants Have Age-Specific Effects on Nevus Count and Predispose to MelanomaThe American Journal of Human Genetics, 2010
- Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapyBritish Journal of Cancer, 2010
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAFNature, 2010
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAFCell, 2010
- Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4Nature Genetics, 2009
- Mutations of the BRAF gene in human cancerNature, 2002